If you like to see more ideas, please subscribe to the premium service "Value in Corporate Events" here and try the free trial. In this service we cover major earnings events, M&A, IPOs and other significant corporate events with actionable ideas. Furthermore, we provide coverage of situations and names on request!In June, I believed that CME Group Inc. (NASDAQ: CME ) was a powerhouse that kept powering on. As a dominant and very profitable exchange, CME delivers on strong growth while posting robust margin ...

If you like to see more ideas, please subscribe to the premium service "Value in Corporate Events" here and try the free trial. In this service we cover major earnings events, M&A, IPOs and other significant corporate events with actionable ideas. Furthermore, we provide coverage of situations and names on request!In June, I believed that CME Group Inc. (NASDAQ: CME ) was a powerhouse that kept powering on. As a dominant and very profitable exchange, CME delivers on strong growth while posting robust margin ...

ConversationBarry IrvinExecutive Chairman Okay, everyone, we are at start time. so as many of you would know, the AGM is a very formal process. Normally I'm a more relaxed presenter, but for the purpose of the AGM, this is being live streamed, and of course, is a very important and formal meeting, so I will be reading from a script, which has already been released online. So to commence. Welcome to the Bega Annual General Meeting, which is being recorded and webcast. Here we are. As we have a quorum, I now ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________________ FORM 10-Q _________________________________________________________ (Mark One) | Delaware | 36-4459170 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | Identification No.) | ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30 ...

Institutional investors are pouring into CME Group’s regulated crypto derivatives markets, setting a series of records across futures and options tied to ether (ETH), solana (SOL) and XRP, CME told CoinDesk on Thursday. Since October 10, open interest across CME's crypto futures and options has jumped 27%, a surge the exchange attributes to a shift away from offshore markets following a wave of liquidations last week. On Tuesday, open interest in ETH futures reached 48,600 contracts — the highest on reco ...

升级评级 - UBS将UiPath评级上调至中性 目标价从10美元上调至17美元 认为市场对生成式人工智能的短期风险担忧过度[2] - Needham将TransMedics评级上调至买入 目标价148美元 其移植追踪数据显示公司第三季度美国销售额可能超出市场预期[2] - 德意志银行将CME集团评级上调至买入 目标价从266美元上调至300美元 预计公司有机增长举措将推动2026年盈利增长至高个位数百分比[3] - Roth Capital将Core Scientific评级上调至买入 目标价从17美元上调至23.5美元 假设CoreWeave对公司的收购不会完成[4] - 摩根大通将LendingClub评级上调至超配 目标价从17美元上调至22美元 认为公司有更多方式在不产生惩罚性费用的情况下增加贷款发放和利润 预计将推动2026年盈利增长加速[5] 下调评级 - 瑞穗将Enphase Energy评级下调至中性 目标价从50美元下调至37美元 理由包括2026年住宅太阳能需求减少 公司因租赁转换导致市场份额下降 以及新租赁和贷款融资模式成功的不确定性[6] - 瑞穗将Hologic评级下调至中性 目标价78美元 此前公司同意被黑石和TPG管理的基金以每股最高79美元 企业价值最高达183亿美元的价格收购[6] - 富国银行将Tegna评级下调至持股观望 目标价维持在22美元 下调理由与 pending Nexstar 有关[6] - H C Wainwright将Avadel Pharmaceuticals评级下调至中性 目标价从36美元下调至20美元 此前公司达成最终协议 将被Alkermes以每股最高20美元的全现金交易收购[6] - 花旗将Arcturus Therapeutics评级下调至中性 目标价从49美元大幅下调至12美元 原因是其ARCT-032二期试验未能显示对囊性纤维化患者有显著改善[6]

Albert Anthony is the pen name of a Croatian-American business author who is a media contributor on investor platform Seeking Alpha, where he has over +1K followers, & also writes for platforms like Investing dot com and is launching a book on Amazon in 2025 called Real Estate Investment Trusts (REITs): A Fundamental Analysis.The author comes from a non-traditional financial background having been an analyst in the IT sector for several Fortune 500 companies in the US, as well as the technical support team ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.Considering buying CME stock? Here’s what analysts think: Read This Next: Photo via ShutterstockLoading...Loading... ...

Key Takeaways CME Group's Q3 EPS of $2.68 beat estimates by 1.9% but was unchanged year over year. Revenues slipped 2.9% to $1.5B as lower clearing fees and volumes offset gains in other areas. Expenses rose 0.8% while record 25.3M daily contracts marked a 10.4% decline from last year. CME Group Inc. (CME) reported third-quarter 2025 adjusted earnings per share of $2.68, which beat the Zacks Consensus Estimate by 1.9%. The bottom line remains unchanged year over year. Quarterly results reflected declining r ...

CME Group (CME) reported $1.54 billion in revenue for the quarter ended September 2025, representing a year-over-year decline of 3%. EPS of $2.68 for the same period compares to $2.68 a year ago.The reported revenue represents a surprise of +0.81% over the Zacks Consensus Estimate of $1.53 billion. With the consensus EPS estimate being $2.63, the EPS surprise was +1.9%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expe ...